Utility of initial MRI for predicting extent of residual disease after neoadjuvant chemotherapy: Analysis of 70 breast cancer patients

Oncology Reports

Volumn 12, Issue 6, 2004, Pages 1257-1262

  Murata, Yoriko ^a   Ogawa, Yasuhiro ^a   Yoshida, Shoji ^a   Kubota, Kei ^a   Itoh, Satoshi ^a   Fukumoto, Mitsutaka ^a   Nishioka, Akihito ^a   Moriki, Toshiaki ^a   Maeda, Hironori ^a   Tanaka, Yosuke ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Breast cancer; Magnetic resonance imaging; Neoadjuvant chemotherapy; Pathological response; Tumor morphology

Indexed keywords

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; GADOLINIUM;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; HUMAN; IMAGE QUALITY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAGET NIPPLE DISEASE; PATHOLOGY; RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; RADIOGRAPHIC IMAGE ENHANCEMENT; TREATMENT OUTCOME;

EID: 16644367154     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.6.1257     Document Type: Article

References (24)

1. Fisher B, Bryant J, Wolmark N, Mamounas E and Brown A: Effect of preoperative chemotherapy on the outocome of women with operative breast cancer. J Clin Oncol 16: 2672-2685, 1998. (Pubitemid 28363030)
2. Trecate G, Ceglia E, Stabile F, Tesoro-Tess JD, Mariani G, Zambetti M and Musumeci R: Locally advanced breast cancer treated with primary chemotherapy: comparison between magnetic resonance imaging and pathological evaluation of residual disease. Tumori 85: 220-228, 1999. (Pubitemid 29482205)
3. Rouzier R, Extra JM, Carton M, Falcou MC, Vincent-Salomon A, Fourquet A, Pouillart P and Boustyn E: Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol 19: 3828-3835, 2001. (Pubitemid 32880061)
4. Hamada N, Ogawa Y, Nishioka A, Kariya S, Terashima M, Yoshida S, Tochika N. Tanaka Y, Kumon M and Inomata T: Breast-conservation treatment for bilateral breast cancer in five Japanese woman. Oncol Rep 9: 469-474, 2002.
5. Ogawa Y, Nishioka A, Inomata T, Yokota N, Sasaki T, Terashima M, Yoshida S, Tanaka Y and Tochika N: Conservation treatment intensified with tamoxifen and CAF chemotherapy without axillary dissection for early breast cancer patients with clinically-negative axillary nodes. Oncol Rep 6: 801-805, 1999.
6. Tsuboi N, Ogawa Y, Inomata T, Yoshida D, Yoshida S, Moriki T and Kumon M: Changes in the findings of dynamic MRI by preoperative CAF chemotherapy for patients with breast cancer of stage II and III: pathologic correlation. Oncol Rep 6: 727-732, 1999.
7. Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C and Largillier R: Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat 72: 145-152, 2002. (Pubitemid 34407209)
8. Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, Grant MD, Hampe DW, Savino DA and Harms SE: Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78: 91-100, 1996. (Pubitemid 26189909)
9. Weatherall PT, Evans GF, Metzger GJ, Saborrian MH and Leith AM: MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with X-ray mammography and palpation. J Magn Reson Imaging 13: 868-875, 2001. (Pubitemid 32479944)
10. Gilles R, Guinebretiere J-M, Toussaint C, Spielman M, Rietjens M, Petit J-Y, Contesso G, Masselot J and Vael D: Locally advanced breast cancer: contrast-enhanced subtraction MR imaing of response to preoperative chemotherapy. Radiology 191: 633-638, 1994. (Pubitemid 24177877)
11. Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D, Samulski TV and Dewhirst MW: Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 181: 1275-1282, 2003. (Pubitemid 37296403)
12. Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R and Kuhn T: Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 12: 1711-1719, 2002. (Pubitemid 36940255)
13. Rieber A, Nussle K, Merkle E, Kreienberg R, Tomczak R and Brambs HJ: MR mammography: influence of menstrual cycle on the dynamic contrast enhancement of fibrocystic disease. Eur Radiol 9: 1107-1112, 1999.
14. Rieber A, Zcitler H, Rosenthal H, Gorieh J, Kreienberg R, Brambs HJ and Tomczak R: MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol 70: 452-458, 1997. (Pubitemid 27229264)
15. Buadu LD, Murakami J, Murayama S, Hashiguchi N, Sakai S, Masuda K, Toyoshima S, Kuroki S and Ohno S: Breast lesions correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 200: 639-649, 1996. (Pubitemid 26282258)
16. Nakamura S, Kenjo H, Kazama T, Doi O and Suzuki K: Efficacy of 3D-MR mammography for breast conserving surgery after neoadjuvant chemotherapy. Breast Cancer 9: 15-19, 2002.
17. Kawashima H, Matsui O, Suzuki M, Kadoya M, Tawara M, Nonomura A, Noguchi M and Takashima T: Breast cancer in dense breast: detection with contrast-enhanced dynamic MR imaging. JMRI 11: 233-243, 2000. (Pubitemid 30127691)
18. Kuhl CK, Bieling HB, Gieseke J, Kreft BP, Sommer T, Lutterbey G and Schild HH: Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 203: 137-144, 1997. (Pubitemid 27142721)
19. Ikeda T, Jinno H, Matsu A, Masamura S and Kitajima M: The role of neoadjuvant chemotherapy for breast cancer treatment. Breast Cancer 9: 8-14, 2002.
20. Cocconi G, Di Blasio B, Alberti G, Bisagni G, Botti E and Peracchia G: Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res Treat 4: 309-313, 1984. (Pubitemid 15189801)
21. Hayes C, Padhani AR and Leach MO: Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 15: 154-163, 2002. (Pubitemid 34213405)
22. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D and Hylton NM: Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR 179: 1193-1199, 2002. (Pubitemid 35204372)
23. Tan KB, Thamboo TP and Raju GC: Xanthomatous pseudotumor: an usual postchemotherapy phenomenon in breast cancer. Arch Pathol Lab Med 127: 739-741, 2003. (Pubitemid 36613230)
24. Takeuchi N, Fukumoto M, Nishioka A, Akagi N, Murata Y, Takeuchi S, Ogawa Y and Yoshida S: Scintigraphic prediction of response to chemotherapy in patients with breast cancer. Technetium 99m-letrofosmin and thallium-201 dual single photon emission computed tomography. Int J Oncol 20: 53-58, 2002.